These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 12086857)
21. Lymphatic vessels as targets of tumor therapy? Karpanen T; Alitalo K J Exp Med; 2001 Sep; 194(6):F37-42. PubMed ID: 11561002 [No Abstract] [Full Text] [Related]
22. Lymphangiogenic growth factors, receptors and therapies. Lohela M; Saaristo A; Veikkola T; Alitalo K Thromb Haemost; 2003 Aug; 90(2):167-84. PubMed ID: 12888864 [TBL] [Abstract][Full Text] [Related]
23. Lymphangiogenesis, inflammation and metastasis. Schoppmann SF Anticancer Res; 2005; 25(6C):4503-11. PubMed ID: 16334134 [TBL] [Abstract][Full Text] [Related]
24. Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. Kirkin V; Mazitschek R; Krishnan J; Steffen A; Waltenberger J; Pepper MS; Giannis A; Sleeman JP Eur J Biochem; 2001 Nov; 268(21):5530-40. PubMed ID: 11683876 [TBL] [Abstract][Full Text] [Related]
25. Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis. Mimura T; Amano S; Usui T; Kaji Y; Oshika T; Ishii Y Exp Eye Res; 2001 Jan; 72(1):71-8. PubMed ID: 11133184 [TBL] [Abstract][Full Text] [Related]
26. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Jeltsch M; Kaipainen A; Joukov V; Meng X; Lakso M; Rauvala H; Swartz M; Fukumura D; Jain RK; Alitalo K Science; 1997 May; 276(5317):1423-5. PubMed ID: 9162011 [TBL] [Abstract][Full Text] [Related]
27. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204 [TBL] [Abstract][Full Text] [Related]
28. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Krishnan J; Kirkin V; Steffen A; Hegen M; Weih D; Tomarev S; Wilting J; Sleeman JP Cancer Res; 2003 Feb; 63(3):713-22. PubMed ID: 12566318 [TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia. Lymboussaki A; Olofsson B; Eriksson U; Alitalo K Circ Res; 1999 Nov; 85(11):992-9. PubMed ID: 10571529 [TBL] [Abstract][Full Text] [Related]
31. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Cursiefen C; Schlötzer-Schrehardt U; Küchle M; Sorokin L; Breiteneder-Geleff S; Alitalo K; Jackson D Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2127-35. PubMed ID: 12091407 [TBL] [Abstract][Full Text] [Related]
32. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Enholm B; Karpanen T; Jeltsch M; Kubo H; Stenback F; Prevo R; Jackson DG; Yla-Herttuala S; Alitalo K Circ Res; 2001 Mar; 88(6):623-9. PubMed ID: 11282897 [TBL] [Abstract][Full Text] [Related]
33. From angiogenesis to lymphangiogenesis. Plate K Nat Med; 2001 Feb; 7(2):151-2. PubMed ID: 11175837 [No Abstract] [Full Text] [Related]
34. The lymphatic vasculature: recent progress and paradigms. Oliver G; Alitalo K Annu Rev Cell Dev Biol; 2005; 21():457-83. PubMed ID: 16212503 [TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. Achen MG; Roufail S; Domagala T; Catimel B; Nice EC; Geleick DM; Murphy R; Scott AM; Caesar C; Makinen T; Alitalo K; Stacker SA Eur J Biochem; 2000 May; 267(9):2505-15. PubMed ID: 10785369 [TBL] [Abstract][Full Text] [Related]
36. Tumor-induced lymphangiogenesis: a target for cancer therapy? Thiele W; Sleeman JP J Biotechnol; 2006 Jun; 124(1):224-41. PubMed ID: 16497404 [TBL] [Abstract][Full Text] [Related]
37. IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma. Zhao W; Wang J; Zhu B; Duan Y; Chen F; Nian W; Sun J; Zhang B; Tong Z; Chen Z Oncol Rep; 2016 Mar; 35(3):1483-92. PubMed ID: 26706909 [TBL] [Abstract][Full Text] [Related]
38. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Rissanen TT; Markkanen JE; Gruchala M; Heikura T; Puranen A; Kettunen MI; Kholová I; Kauppinen RA; Achen MG; Stacker SA; Alitalo K; Ylä-Herttuala S Circ Res; 2003 May; 92(10):1098-106. PubMed ID: 12714562 [TBL] [Abstract][Full Text] [Related]
39. [Lymphangiogenesis and biological activity ov vascular endothelial growth factor-C]. Mandriota SJ; Pepper MS J Soc Biol; 1999; 193(2):159-63. PubMed ID: 10451350 [TBL] [Abstract][Full Text] [Related]